Tisotumab vedotin
Based on 1 Customer Validation
Tisotumab vedotin is an antibody drug conjugate (ADC) targeting tissue factor (TF), formed by covalently linking a fully human monoclonal antibody (TF-011) against TF with the microtubule disruptor Monomethyll Auristatin E (MMAE) (HY-15162), and the drug-linker conjugate for ADC is VcMMAE (HY-15575). Tisotumab vedotin has immunomodulatory and anti-tumor activities, and can be used in the study of advanced or metastatic solid tumors such as cervical cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit : 95.28%
- CAS. Nr.: 1418731-10-8
- Molecular Weight:152000 (average)
-
Speicherung:
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
HY-141601
Telisotuzumab vedotinAnti-c-MET ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-132253
Polatuzumab vedotinMicrotubule Inhibitor -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-P3239
Belantamab mafodotinAnti-BCMA ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-132258A
Mirvetuximab soravtansine (solution)ADC -
HY-P99813
Patritumab deruxtecanHER3-Directed ADC -
HY-138298
Trastuzumab deruxtecan (solution)HER2 ADC
Biologische Aktivität
Beschreibung
IC50 & Target
tissue factor[1].
In Vitro
Tisotumab vedotin induces immunogenic cell death in tumor cells expressing TF, leading to the release of endoplasmic reticulum stress markers, ATP, and high mobility histone B1 (HMGB1)[1]. Tisotumab vedotin induces anti-tumor activity through MMAE mediated cytotoxicity, Fc mediated antibody dependent cell phagocytosis (ADCP), and Fab mediated protease activated receptor 2 (PAR-2) signaling inhibition[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HPAF-II, SCID mice[4].
-
Dosage:2 mg/kg
-
Administration:Once daily; 25 days
-
Result:Decreased the tumor volume over the 3-week window.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 1418731-10-8
-
Appearance Liquid
-
Molecular Weight 152000 (average)
-
Color Colorless to light yellow
-
SMILES
[Tisotumab vedotin]
-
Versand
Shipping with dry ice.
-
Speicherung
-80°C, protect from light
Reinheit & Dokumentation
-
Data Sheet (273 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
Verweise
[3]. Luu K, et al. A review of the novel tissue factor antibody-drug conjugate: Tisotumab vedotin. J Oncol Pharm Pract. 2023 Mar;29(2):441-449. [Content Brief]
[4]. Rubahamya B, et al. Clinical translation of antibody drug conjugate dosing in solid tumors from preclinical mouse data. Sci Adv. 2024 May 31;10(22):eadk1894. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Tisotumab vedotin Related Classifications
HY-152963 Related Classifications
Powered by Bioz